Phase I Study of the Combination of MLN9708 and Fulvestrant

NCT02384746 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Breast Cancer

Interventions

DRUG: Fulvestrant
DRUG: MLN9708

Sponsor

Dartmouth-Hitchcock Medical Center